Annamycin is under clinical development by Moleculin Biotech and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Annamycin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
L-Annamycin is under development for the treatment of relapsed or refractory acute myelogeneous leukemia (AML), metastatic lung cancer, metastatic melanoma, soft-tissue sarcomas with pulmonary metastases, metastatic lung sarcoma, reticulosarcoma, metastatic pancreatic cancer (liver mets/pancreatic), liposarcoma, leiomyosarcoma, synovial sarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, malignant peripheral nerve sheath tumour, malignant solitary fibrous tumour, and pleomorphic RMS and metastatic osteosarcoma. The drug candidate is administered intravenously. L-Annamycin is a liposome nanoparticle formulation of annamycin, a second generation anthracycline. It is a liposome-encapsulated form of the semi-synthetic doxorubicin analogue annamycin with antineoplastic activity. It acts by targeting DNA topoisomerase II. It was under development for the treatment of relapsed and refractory acute lymphocytic leukemia (ALL).
Moleculin Biotech overview
Moleculin Biotech (MBI) is a clinical stage pharmaceutical company. It offers development of novel drugs for oncology. The company’s lead product candidate Annamycin is an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). It also develops WP1066, an immuno-stimulating STAT3 inhibitor, for treatment of brain tumors, pancreatic cancer and AML; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. The company works in collaboration with The University of Texas MD Anderson Cancer Center, and Dermin SP ZOO to develop its product portfolio. MBI is headquartered in Houston, Texas, the US.
For a complete picture of Annamycin’s drug-specific PTSR and LoA scores, buy the report here.